Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses.

Trial Profile

Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Apr 2016 Final results presented at the 68th Annual Meeting of the American Academy of Neurology
    • 25 Apr 2015 Results of 12 years presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 30 Mar 2015 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top